Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019

Le résumé fourni par la source

OBJECTIVES: To survey trends in antimicrobial resistance among the pathogens of hospital-acquired lower respiratory tract infection (HA-LRTI), which causes significant mortality and morbidity, particularly among ventilated patients. METHODS: The BSAC Surveillance collected quotas of major HA-LRTI pathogens from sentinel sites from 2008/09 (October to September) to 2018/19. MIC testing was by BSAC agar dilution. Resistance mechanisms were inferred from synergy tests, interpretive reading and PCR. RESULTS: Target numbers of Staphylococcus aureus, Pseudomonas aeruginosa and Enterobacterales-dominated by Escherichia coli and Klebsiella spp.-were reliably collected. Acinetobacter spp. collections were small, reflecting low incidence. Resistance rates fell or fluctuated, with no major rises. Notable declines included: (i) a fall in the proportion of MRSA among S. aureus from c. 40% to 10%; (ii) a halving, since 2012/13, in 'triple-resistance' to carbapenems, aminoglycosides and fluoroquinolones among Acinetobacter baumannii sensu stricto, from c. 24% to 9%; (iii) reductions in AmpC-associated cephalosporin resistance among Enterobacter cloacae and Serratia isolates, and (iv) falls in fluoroquinolone resistance among Enterobacterales, except Klebsiella pneumoniae. Resistance rates in P. aeruginosa remained low, though higher than in bacteraemia. Cephalosporin resistance in E. coli and K. pneumoniae was largely ESBL associated and, unlike AmpC-associated resistance in Enterobacter and Serratia spp., did not decline notably. Except for OXA-23 in A. baumannii, carbapenemases remained extremely rare. Antistaphylococcal oxazolidinones, tigecycline, ceftolozane/tazobactam, ceftazidime/avibactam and ceftobiprole retained uneroded activity. CONCLUSIONS: From 2008/09 to 2018/19, there were no major rises in resistance among the principal agents of HA-LRTI; for several important organisms/resistance combinations there were notable declines.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.